Published on 02/07/2012
The NHS will decrease the amount it spends on new drugs over the next few years, according to an economic forecast.
In a preliminary forecast from the Office of Health Economics, patients without health insurance will have slower access to new treatments compared with the rest of Europe.
Research commissioned by the Association of the British Pharmaceutical Industry (ABPI) shows that expenditure on new branded medicines by the NHS is set to shrink over the next three years.
Although the total amount spent on the NHS is set to rise by 2.5 per cent a year between 2011 and 2015, spending on new medicines will rise just 1.3 per cent annually.
In three years’ time, medicines launched between 2012 and 2015 will account for less than 2 per cent of the total spend on medicines.
Stephen Whitehead, Chief Executive of the ABPI, said: “I am deeply concerned that these savings are not being reinvested back into the system because these figures show our spending on the newest and most advanced medicines is declining in real terms.
This spells bad news for the discovery of new life saving medicines and ultimately the health and well-being of UK patients.”
Recently developed drugs include Abiraterone for prostate cancer and Zelboraf for skin cancer.
© ActiveQuote Ltd. 2012Categories: NHS and Hospitals